Related Experiment Video
Updated: Jul 20, 2026
06:59
Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
[Study on apoE gene polymorphism in Chinese type II b hyperlipidemia]
Hua Xi Yi Ke Da Xue Xue Bao = Journal of West China University of Medical Sciences = Huaxi Yike Daxue Xuebao
|February 26, 2003
Summary
Apolipoprotein E (apoE) gene variations influence lipid levels in Chinese patients with type IIb hyperlipoproteinemia. Alleles epsilon 2 and epsilon 4 are linked to altered triglyceride, cholesterol, and apolipoprotein levels, impacting cardiovascular risk.
Area of Science:
- Genetics and Molecular Biology
- Cardiovascular Research
- Biochemistry
Context:
- Type IIb hyperlipoproteinemia is a dyslipidemic condition characterized by elevated triglycerides and cholesterol.
- Apolipoprotein E (apoE) plays a crucial role in lipoprotein metabolism.
- Understanding apoE polymorphism in diverse populations is vital for personalized medicine.
Purpose:
- To investigate the association between apolipoprotein E (apoE) gene polymorphism and plasma lipid and apolipoprotein levels.
- To analyze apoE genotypes using polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP).
- To compare lipid and apolipoprotein profiles between 74 Chinese patients with type IIb hyperlipoproteinemia and 230 healthy controls.
Summary:
- Patients with type IIb hyperlipoproteinemia exhibited significantly higher serum triglycerides (TG), total cholesterol (TC), LDL-C, non-HDL-C, and specific apolipoproteins (apoA II, apoB100, apoC II, apoC III, apoE) compared to controls.
- The apoE3/3 genotype and epsilon 3 allele were most frequent in both groups. Allele epsilon 2 showed a trend towards increase, while epsilon 4 showed a trend towards decrease in patients.
- Specific apoE genotypes were linked to lipid profiles: apoE2 associated with higher TG and apoC II/apoE levels; apoE4 associated with higher TC, non-HDL-C, and apoE levels.
Impact:
- The study highlights the influence of apoE alleles epsilon 2 and epsilon 4 on serum lipid and apolipoprotein levels in Chinese individuals with type IIb hyperlipoproteinemia.
- Findings contribute to understanding the genetic underpinnings of dyslipidemia in this population.
- This knowledge may aid in risk stratification and targeted therapeutic strategies for hyperlipoproteinemia.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...